The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BCAB | -65.27% | N/A | N/A | -98% |
| S&P | +18.33% | +108.18% | +15.79% | +86% |
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.12M | 49.8% |
| Gross Margin | 97.93% | 0.0% |
| Market Cap | $23.13M | -64.9% |
| Market Cap / Employee | $0.30M | 0.0% |
| Employees | 76 | 16.9% |
| Net Income | -$18.71M | 11.2% |
| EBITDA | -$18.53M | 14.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $18.21M | -70.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $5.24M | 0.0% |
| Short Term Debt | $0.81M | -51.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -124.29% | -40.1% |
| Return On Invested Capital | -156.30% | -110.4% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$16.65M | 46.0% |
| Operating Free Cash Flow | -$14.20M | 26.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.70 | 1.24 | 1.41 | 42.26 | 3088.18% |
| Price to Sales | 7.73 | 2.68 | 1.84 | 2.11 | - |
| Price to Tangible Book Value | 3.70 | 1.24 | 1.41 | 42.28 | 3089.45% |
| Enterprise Value to EBITDA | -2.70 | 1.17 | 0.67 | -0.59 | 113.28% |
| Return on Equity | -139.1% | -164.3% | -246.2% | -813.9% | 506.72% |
| Total Debt | $1.25M | $0.84M | $0.55M | $6.05M | 263.72% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
